• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market

    ID: MRFR/HC/25490-HCR
    128 Pages
    Rahul Gotadki
    October 2025

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Research Report By Treatment Type (Medication, Liver Transplantation, Other Treatments), By Drug Class (Bile Acid Resins, Ursodeoxycholic Acid, Others), By Route of Administration (Oral, Intravenous, Others), By Severity of Disease (Mild, Moderate, Severe) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Infographic
    Purchase Options
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Summary

    The Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is projected to grow from 0.09 USD Billion in 2024 to 0.17 USD Billion by 2035.

    Key Market Trends & Highlights

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Key Trends and Highlights

    • The market is expected to achieve a compound annual growth rate of 6.49 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 0.18 USD Billion, indicating robust growth potential.
    • in 2024, the market is valued at 0.09 USD Billion, reflecting the current demand for treatment options.
    • Growing adoption of innovative therapies due to increasing awareness of Progressive Familial Intrahepatic Cholestasis Type 2 is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.09 (USD Billion)
    2035 Market Size 0.17 (USD Billion)
    CAGR (2025-2035) 6.21%

    Major Players

    Pfizer, Novartis, Johnson Johnson, Genfit, Roche, Merck, Intercept Pharmaceuticals, GlaxoSmithKline, Bristol Myers Squibb, Eli Lilly, Albireo Pharma, Madrigal Pharmaceuticals, Bayer, BridgeBio Pharma, Mirum Pharmaceuticals

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Trends

    Key market drivers for the Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2) Treatment Market include the rising prevalence of PFIC2, growing awareness of the disease, and advancements in therapeutic approaches. The market is witnessing a surge in demand for effective and innovative treatments due to the unmet medical needs of patients. Opportunities for growth lie in the development of novel therapies, such as gene therapies and targeted therapies, that address the underlying genetic defects causing PFIC2. Recent trends indicate a shift towards personalized medicine, with a focus on tailored treatment regimens based on individual patient characteristics.

    The market is expected to continue expanding as research efforts yield promising new treatment options and improve patient outcomes.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    The increasing recognition of Progressive Familial Intrahepatic Cholestasis Type 2 as a critical genetic disorder is likely to drive advancements in treatment options and enhance patient care.

    National Institutes of Health (NIH)

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drivers

    Increasing Prevalence of Genetic Disorders

    The rising incidence of genetic disorders, particularly Progressive Familial Intrahepatic Cholestasis Type 2, is a notable driver for the Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Industry. As awareness of genetic conditions grows, more patients are being diagnosed, leading to an increased demand for effective treatments. This trend is underscored by the projected market value of 0.09 USD Billion in 2024, which is expected to rise to 0.18 USD Billion by 2035. The compound annual growth rate (CAGR) of 6.49% from 2025 to 2035 reflects the urgency for innovative therapies in this space.

    Market Segment Insights

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Treatment Type Insights

    The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is segmented on the basis of Treatment Type into Medication, Liver Transplantation, and Other Treatments. The Medication segment is the most prominent one in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market. Progressive familial intrahepatic cholestasis type 2 can be treated using medications including ursodeoxycholic acid, obeticholic acid, and fibrates.

    Liver transplantation entails a surgical procedure in which the diseased liver of a patient is replaced with the liver of a healthy donor.Liver transplantation is a last resort treatment for patients who suffer from the end stage of Progressive Familial Intrahepatic Cholestasis Type 2. The other treatments include supportive care, such as dietary modifications, cholestyramine, and plasmapheresis, that are required to be adopted by the patients. The medication segment is anticipated to grow at a steady pace in the future market owing to more adoption of ursodeoxycholic acid and the development of new medications.

    Liver transplantation is anticipated to grow at a stable rate in the future, while the other treatment is expected to grow at a moderate pace.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drug Class Insights

    Bile Acid Resins, Ursodeoxycholic Acid, and Others constitute the drug class segment in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market. Bile Acid Resins accounted for the largest revenue share in 2023, owing to their efficacy in reducing pruritus and improving liver function. Ursodeoxycholic Acid is expected to witness the fastest growth rate during the forecast period due to its ability to improve bile flow and reduce liver inflammation. Others, which include experimental and emerging therapies, are anticipated to contribute a significant share to the market growth.

    The increasing prevalence of Progressive Familial Intrahepatic Cholestasis Type 2, coupled with the rising demand for effective treatment options, is driving the growth of the drug class segment.

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Route of Administration Insights

    The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market segmentation by Route of Administration includes Oral, Intravenous, and Others. The Oral segment is anticipated to hold the largest share of the market in 2023, accounting for around 65%. This dominance can be attributed to the ease of administration, patient convenience, and cost-effectiveness of oral medications.

    The Intravenous segment is projected to witness steady growth over the forecast period, owing to the increasing adoption of injectable therapies for severe cases of Progressive Familial Intrahepatic Cholestasis Type 2.The Others segment, which includes topical and transdermal formulations, is expected to gain traction due to the growing demand for non-invasive and localized treatment options. The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market revenue for the Oral segment is estimated to reach USD 0.34 billion by 2032, while the Intravenous segment is projected to generate USD 0.15 billion by the same year.

    Get more detailed insights about Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Research Report-Forecast Till 2032
    Request Free Sample

    Regional Insights

    The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is segmented into North America, Europe, APAC, South America, and MEA. The regional market segmentation provides insights into the market's growth potential, size, and key trends.

    North America is expected to hold the largest share of the global market in 2023, owing to the presence of key market players and a high prevalence of PFIC2. Europe is expected to witness steady growth, driven by increasing awareness about PFIC2 and the availability of advanced treatment options.APAC is anticipated to register a significant growth rate, due to rising healthcare expenditure and increasing investment in research and development activities. South America and MEA are expected to experience moderate growth, owing to limited access to specialized healthcare facilities and lower healthcare expenditure.

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Regional Insights

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    Major players in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market industry are actively involved in research and development activities to strengthen their product portfolios and gain a competitive edge. Leading Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market players are focused on expanding their geographical presence and forming strategic alliances to cater to the growing patient population.

    The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is witnessing a surge in mergers and acquisitions as companies seek to consolidate their market position and gain access to innovative technologies. Key players are also investing in the development of novel treatment approaches, such as gene therapy and stem cell therapy, to address unmet medical needs in the treatment of Progressive Familial Intrahepatic Cholestasis Type 2.A leading company in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is focused on providing comprehensive care to patients with cholestatic liver diseases.

    The company offers a range of products and services, including diagnostic tests, therapies, and support programs. It has a strong presence in major markets and is actively expanding its geographical reach through strategic collaborations and acquisitions. The company is committed to investing in research and development to discover and develop innovative treatments for Progressive Familial Intrahepatic Cholestasis Type 2 and other cholestatic liver diseases.A prominent competitor in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is known for its expertise in the development and commercialization of orphan drugs.

    The company has a robust pipeline of potential therapies for rare diseases, including Progressive Familial Intrahepatic Cholestasis Type 2. It is focused on leveraging its strong commercial infrastructure and partnerships with patient advocacy groups to drive market penetration and improve patient access to its treatments. The company is committed to working closely with healthcare professionals and researchers to advance the understanding and management of Progressive Familial Intrahepatic Cholestasis Type 2 and other rare liver diseases.

    Key Companies in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market market include

    Industry Developments

    The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is projected to grow from USD 0.09 billion in 2024 to USD 0.15 billion by 2032, exhibiting a CAGR of 6.21%. This growth is attributed to the rising prevalence of the disease, increasing awareness of treatment options, and the development of novel therapies.Recent news developments include the approval of obeticholic acid by the FDA in 2023 for the treatment of PFIC2 and the initiation of clinical trials for several promising new therapies. Major players in the market include Albireo Pharma, Inc., Mirum Pharmaceuticals, Inc., and Gilead Sciences, Inc.

    Key market dynamics include strategic collaborations and partnerships between pharmaceutical companies and research institutions to accelerate drug development and commercialization.

    Future Outlook

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Future Outlook

    The Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is projected to grow at a 6.21% CAGR from 2025 to 2035, driven by advancements in gene therapy and increasing awareness.

    New opportunities lie in:

    • Invest in gene therapy research to enhance treatment efficacy and patient outcomes.
    • Develop patient-centric digital health solutions for better disease management.
    • Expand global distribution networks to improve access in underserved regions.

    By 2035, the market is expected to exhibit robust growth, reflecting advancements in treatment options and increased patient access.

    Market Segmentation

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drug Class Outlook

    • Bile Acid Resins
    • Ursodeoxycholic Acid
    • Others

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Treatment Type Outlook

    • Medication
    • Liver Transplantation
    • Other Treatments

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Severity of Disease Outlook

    • Mild
    • Moderate
    • Severe

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Route of Administration Outlook

    • Oral
    • Intravenous
    • Others

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024 0.09(USD Billion)
    Market Size 2035 0.17 (USD Billion)
    Compound Annual Growth Rate (CAGR) 6.21% (2025 - 2035)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2019 - 2023
    Market Forecast Units USD Billion
    Key Companies Profiled Pfizer, Novartis, Johnson Johnson, Genfit, Roche, Merck, Intercept Pharmaceuticals, GlaxoSmithKline, Bristol Myers Squibb, Eli Lilly, Albireo Pharma, Madrigal Pharmaceuticals, Bayer, BridgeBio Pharma, Mirum Pharmaceuticals
    Segments Covered Treatment Type, Drug Class, Route of Administration, Severity of Disease, Regional
    Key Market Opportunities Targeted therapies Novel drug discovery Genetic testing amp screening Artificial intelligence Telehealth
    Key Market Dynamics Growing prevalence of PFIC2 Launch of novel therapies Rise in government initiatives Expansion of patient support organizations Increasing awareness about PFIC2.
    Countries Covered North America, Europe, APAC, South America, MEA
    Market Size 2025 0.10 (USD Billion)

    FAQs

    What is the market size of the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market?

    The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is expected to reach USD 0.15 billion by 2032, exhibiting a CAGR of 6.21% during the forecast period (2024-2032).

    Which region is expected to dominate the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market?

    North America is expected to dominate the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, accounting for the largest share due to the high prevalence of the disease and the presence of major market players in the region.

    What are the key growth drivers of the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market?

    The key growth drivers of the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market include the increasing prevalence of the disease, the growing demand for effective treatment options, and the rising healthcare expenditure.

    What are the key applications of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment?

    Progressive Familial Intrahepatic Cholestasis Type 2 Treatment is primarily used for the treatment of progressive familial intrahepatic cholestasis type 2, a rare genetic disorder that affects the liver.

    Who are the key competitors in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market?

    The key competitors in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market include Albireo Pharma, Inc., Mirum Pharmaceuticals, Inc., and Novartis AG.

    What is the expected CAGR of the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market?

    The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is expected to exhibit a CAGR of 6.21% during the forecast period (2024-2032).

    What factors are expected to restrain the growth of the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market?

    The growth of the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market may be restrained by the high cost of treatment and the limited number of approved therapies.

    What are the key trends that are shaping the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market?

    The key trends shaping the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market include the growing focus on precision medicine and the development of new therapies.

    What are the challenges faced by the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market?

    The challenges faced by the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market include the lack of awareness about the disease and the limited access to treatment in developing countries.

    What are the opportunities for growth in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market?

    The opportunities for growth in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market include the rising prevalence of the disease and the increasing demand for effective treatment options.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Stories
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027